RESUMO
Herpes zoster can present many uncertainties for consulting dermatologists. We review the current guidelines and recent literature on important issues that arise in the care of hospitalized patients with herpes zoster, including infection control isolation practices, treatment courses for zoster and acute zoster-associated pain, and indications for long-term prophylaxis. We present the findings of an inpatient zoster management practices survey of the membership of the Society of Dermatology Hospitalists, an expert resource group of the American Academy of Dermatology, and discuss directions for future investigation and potential opportunities for management improvements in light of these collective data.
Assuntos
Aciclovir/uso terapêutico , Controle de Doenças Transmissíveis/organização & administração , Herpes Zoster/tratamento farmacológico , Herpes Zoster/transmissão , Herpesvirus Humano 3/patogenicidade , Hospitalização/estatística & dados numéricos , Adulto , Antivirais/uso terapêutico , California , Estudos Transversais , Medicina Baseada em Evidências , Feminino , Herpes Zoster/diagnóstico , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Prognóstico , Medição de Risco , Índice de Gravidade de Doença , Resultado do TratamentoAssuntos
Coinfecção/diagnóstico , Doença de Darier/patologia , Leishmaniose Tegumentar Difusa/patologia , Dermatopatias Parasitárias/patologia , Adulto , Anfotericina B/administração & dosagem , Anfotericina B/uso terapêutico , Antiprotozoários/administração & dosagem , Doença de Darier/diagnóstico , Quimioterapia Combinada , Infecções por HIV/complicações , Infecções por HIV/virologia , Humanos , Infusões Intravenosas/métodos , Leishmaniose Tegumentar Difusa/complicações , Leishmaniose Tegumentar Difusa/tratamento farmacológico , Leishmaniose Tegumentar Difusa/parasitologia , Masculino , Fosforilcolina/administração & dosagem , Fosforilcolina/análogos & derivados , Fosforilcolina/uso terapêutico , Resultado do Tratamento , Trypanosoma cruzi/isolamento & purificaçãoAssuntos
Hispânico ou Latino/estatística & dados numéricos , Transplante de Órgãos/efeitos adversos , Dermatopatias/epidemiologia , Neoplasias Cutâneas/epidemiologia , Transplantados/estatística & dados numéricos , Negro ou Afro-Americano/estatística & dados numéricos , Idoso , Asiático/estatística & dados numéricos , Humanos , Incidência , Pessoa de Meia-Idade , Estudos Retrospectivos , Dermatopatias/etiologia , Neoplasias Cutâneas/etiologia , Estados Unidos/epidemiologiaAssuntos
Histiocitose Sinusal/tratamento farmacológico , Histiocitose Sinusal/patologia , Metotrexato/administração & dosagem , Prednisona/administração & dosagem , Idoso de 80 Anos ou mais , Biópsia por Agulha , Quimioterapia Combinada , Histiocitose Sinusal/diagnóstico , Humanos , Imuno-Histoquímica , Masculino , Doenças Raras , Índice de Gravidade de Doença , Pele/patologia , Resultado do TratamentoAssuntos
Histiocitose Sinusal/tratamento farmacológico , Histiocitose Sinusal/patologia , Metotrexato/uso terapêutico , Prednisona/uso terapêutico , Pele/patologia , Idoso de 80 Anos ou mais , Biópsia por Agulha , Seguimentos , Humanos , Imuno-Histoquímica , Masculino , Doenças Raras , Medição de Risco , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
A variety of common dermatoses are known to have drug-induced variants. This article discusses the clinical presentation, time frames, reported culprit medications, pathophysiology and management of drug-induced lupus, cutaneous vasculitis, pemphigus, pemphigoid, linear IgA bullous dermatosis, Sweet's syndrome, erythema nodosum, pyoderma gangrenosum, pseudolymphoma, lichen planus, and psoriasis.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Dermatopatias/induzido quimicamente , Humanos , Lúpus Eritematoso Sistêmico/induzido quimicamente , Pseudolinfoma/induzido quimicamente , Vasculite Leucocitoclástica Cutânea/induzido quimicamenteRESUMO
BACKGROUND: Merkel cell carcinoma (MCC) is among the deadliest of cutaneous malignancies. A lack of consensus evaluation and treatment guidelines has hindered management of this disease. The utility of simultaneous positron emission tomography and computed tomography (PET/CT) has been demonstrated for a variety of tumors yet remains underinvestigated for MCC. OBJECTIVES: To report the value of fluorodeoxyglucose PET/CT imaging in the initial staging and ongoing management of individuals with MCC and to determine whether any patient or tumor characteristics may predict when PET/CT is more likely to have greater influence on medical decision-making. MATERIALS AND METHODS: A single-institution retrospective chart review was conducted of all patients diagnosed with MCC who underwent FDG-PET/CT scanning from 2007 to 2010. The outcome of each of these studies was evaluated as to the influence on patient staging and management. Patient clinical information and information on gross and microscopic tumor characteristics were collected and analyzed. RESULTS: Twenty patients underwent 39 PET/CT scans. Results of PET/CT imaging revealed previously unknown information related to MCC in four (20%) patients, leading to changes in management in three of these four cases. Three previously unknown neoplasms were detected. CONCLUSION: Fluorodeoxyglucose-positron emission tomography and computed tomography is a valuable tool for initial staging and to assess response to therapy of patients diagnosed with MCC. Larger prospective studies would be required to establish the optimal timing for this imaging modality.
Assuntos
Carcinoma de Célula de Merkel/diagnóstico por imagem , Carcinoma de Célula de Merkel/secundário , Imagem Multimodal , Tomografia por Emissão de Pósitrons , Neoplasias Cutâneas/diagnóstico por imagem , Neoplasias Cutâneas/patologia , Tomografia Computadorizada por Raios X , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Célula de Merkel/terapia , Feminino , Fluordesoxiglucose F18 , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Compostos Radiofarmacêuticos , Estudos Retrospectivos , Neoplasias Cutâneas/terapiaRESUMO
Pityriasis rubra pilaris (PRP) is a rare condition characterized by red-orange plaques with islands of sparing with follicular and palmoplantar hyperkeratosis. The disease can be difficult to treat and often requires patients to trial multiple therapeutic options. In recent years, targeted biologic therapies have increasingly been trialed due to their relative efficacy and favorable safety profile. Ixekizumab, an interleukin-17 inhibitor, is one such therapy that has demonstrated efficacy in PRP with few reported adverse events. We present a PRP patient who developed Kaposi's varicelliform eruption followed by a pseudomonal superinfection three months after initiation of ixekizumab.
RESUMO
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. Disease progression usually occurs via lymphatic spread to regional lymphatic draining basins, followed by distant metastasis. We report the clinical course, histopathology and genetic analysis of a 69-year-old woman with likely hematogenous spread of cutaneous neuroendocrine carcinoma manifesting as a single metastatic lesion to a distant cutaneous site. Although the possibility of two cutaneous primary MCCs was considered, array comparative genomic hybridization (aCGH) identified identical distal amplification of a region of chromosome 12p, and synchronous loss of chromosomes 8p and 17p, effectively ruling out the possibility of independent primaries. We propose that this represents a primary cheek MCC with rapid, isolated cutaneous metastasis to the contralateral ankle via hematogenous spread. The distinction between a second primary MCC and a distant cutaneous metastasis clearly has important implications with regard to staging, treatment and prognosis. To our knowledge, this represents the first report of the use of aCGH to clarify the relationship of multiple synchronous cutaneous MCCs and the first report of a single distant cutaneous focus of hematogenous spread. Our data calls into question prior reports alleging multiple cutaneous primaries of this very rare tumor.
Assuntos
Carcinoma de Célula de Merkel/patologia , Segunda Neoplasia Primária/etiologia , Neoplasias Cutâneas/patologia , Idoso , Carcinoma de Célula de Merkel/genética , Carcinoma de Célula de Merkel/terapia , Terapia Combinada , Hibridização Genômica Comparativa , DNA de Neoplasias/análise , Diagnóstico Diferencial , Feminino , Humanos , Neoplasias Cutâneas/genética , Neoplasias Cutâneas/terapiaRESUMO
Nodular secondary syphilis is an uncommon variant of secondary syphilis. We identified three cases of nodular secondary syphilis at our institution. The first patient presented with a diffuse nodular rash that included his scrotum and penis. The second patient had disseminated skin-colored nodules with serosanguinous crust on his face, trunk, and extremities. The third patient had a pruritic papular and nodular rash with overlying crust. All three patients had a reactive rapid plasma reagin and tested positive for fluorescent treponemal antibody absorption. All were eventually confirmed to be human immunodeficiency virus-positive. Histopathological examination demonstrated inflammatory infiltrate in the dermis composed of lymphocytes, histiocytes, and plasma cells, and treponemal staining highlighted spirochetes in the dermis. The patients were successfully treated with intramuscular penicillin benzathine G. Physicians should be aware of nodular syphilis as a less common cutaneous manifestation of secondary syphilis. Prompt diagnosis of secondary syphilis can expedite resolution of the infection and avoid progression to tertiary syphilis.
Assuntos
Soropositividade para HIV/complicações , Penicilina G Benzatina/uso terapêutico , Sífilis/tratamento farmacológico , Treponema pallidum/isolamento & purificação , Adulto , Exantema/patologia , Humanos , Masculino , Penicilina G Benzatina/administração & dosagem , Sífilis/diagnóstico , Sorodiagnóstico da Sífilis , Sífilis Cutânea/patologia , Resultado do Tratamento , Treponema pallidum/imunologiaRESUMO
The neurofibromatosis 2 locus (NF2) is inactivated through mutation and loss of heterozygosity (LOH) in 40-65% of all sporadic meningiomas, while the role of the p53 tumor suppression pathway in meningioma initiation and progression is still unclear. This study aims to determine if a p53 codon 72 arginine-to-proline polymorphism, found to be correlated with cancer development and cancer patient survival in other tumors, is associated with sporadic meningioma initiation or progression. We investigated Pro72 incidence in a cohort of 92 sporadic meningiomas and analyzed its association with histological grade (WHO classification) and with NF2 LOH (determined using polymorphic microsatellite markers on 22q). The Pro72 allele was not found to be selected for in the cohort. However, in the subgroup of meningiomas with NF2 LOH and carrying Pro72, 50.0% had high grade tumors (WHO grades II and III) compared to only 14.3% of those without NF2 LOH (OR = 6.0, CI = 1.56-23.11, P = 0.012). The significant association occurred only when considering subgroups of meningiomas with or without NF2 LOH, suggesting that not including NF2 status when analyzing study cohorts may explain the variability seen in the literature where all meningiomas were grouped together. Our data suggests a role for the p53 pathway in the progression of meningiomas in which NF2 is inactivated, and highlights the importance of accounting for NF2 LOH in future studies of meningiomas and the p53 pathway.
Assuntos
Neoplasias Meníngeas/patologia , Meningioma/patologia , Neurofibromatose 2/patologia , Transdução de Sinais/fisiologia , Proteína Supressora de Tumor p53/fisiologia , Idoso , Arginina/genética , Estudos de Coortes , Intervalos de Confiança , Análise Mutacional de DNA/métodos , Progressão da Doença , Feminino , Humanos , Perda de Heterozigosidade , Masculino , Neoplasias Meníngeas/complicações , Neoplasias Meníngeas/metabolismo , Neoplasias Meníngeas/mortalidade , Meningioma/complicações , Meningioma/metabolismo , Meningioma/mortalidade , Pessoa de Meia-Idade , Neurofibromatose 2/complicações , Neurofibromatose 2/genética , Razão de Chances , Polimorfismo Genético/genética , Prolina/genética , Estudos Retrospectivos , Transdução de Sinais/genética , Proteína Supressora de Tumor p53/genéticaRESUMO
The NF2 tumor suppressor gene on chromosome 22 is a member of the protein 4.1 family of cytoskeletal elements. A number of single- and multiple-tumor phenotypes have been linked to alterations of NF2 since its characterization in 1993. We present a meta-analysis of 967 constitutional and somatic NF2 alterations from 93 published reports, along with 59 additional unpublished events identified in our laboratory and 115 alterations identified in clinical samples submitted to the Massachusetts General Hospital (MGH) Neurogenetics DNA Diagnostic Laboratory. In total, these sources defined 1,070 small genetic changes detected primarily by exon scanning, 42 intragenic changes of one whole exon or larger, and 29 whole gene deletions and gross chromosomal rearrangements. Constitutional single-exon events (N=422) were significantly more likely to be nonsense or splice site changes than somatic events (N=533), which favored frameshift changes (chi(2) test; P<0.001). Somatic events also differed markedly between tumors of different pathology, most significantly in the tendency of somatic events in meningiomas to lie within the 5' FERM domain of the transcript (Fisher's exact test; P<0.01 in comparison to schwannomas) with a complete absence of mutations in exons 14 and 15. There was no statistically significant difference in mutation type or exon distribution between published constitutional events and those found by the clinical laboratory. Less than 10% of all published and unpublished small alterations are nontruncating (N=63) and these changes are clustered in exons 2 and 3, suggesting that this region may be especially crucial to tumor suppressor activity in the protein.
Assuntos
Genes da Neurofibromatose 2 , Técnicas de Diagnóstico Molecular/métodos , Mutação , Análise Citogenética , Genes Supressores de Tumor/fisiologia , Genótipo , Humanos , Fenótipo , Polimorfismo GenéticoAssuntos
Analgésicos/uso terapêutico , Gabapentina/uso terapêutico , Leiomiomatose/complicações , Nifedipino/uso terapêutico , Dor Intratável/tratamento farmacológico , Neoplasias Cutâneas/complicações , Adulto , Feminino , Humanos , Leiomiomatose/patologia , Dor Intratável/etiologia , Neoplasias Cutâneas/patologiaRESUMO
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by painful, necrotic ulceration. It typically affects patients in the third to sixth decades of life, with almost equal incidence in men and women. PG occurs most frequently on the lower extremities. Five clinical variants are currently recognized: classic, bullous, pustular, vegetative, and peristomal types. Half of PG cases are seen in association with systemic disease. Mimickers include infection, vascular insufficiency ulcers, systemic vasculitides, autoimmune disease, cancer, and exogenous tissue injury, among others. PG is often a diagnosis of exclusion, as there are no specific laboratory or histopathologic findings to confirm the diagnosis. PG thus presents many clinical challenges: it is difficult to diagnose, is frequently misdiagnosed, and often requires a work-up for underlying systemic disease. Successful management of PG typically requires multiple modalities to reduce inflammation and optimize wound healing, in addition to treatment of any underlying diseases. Prednisone and cyclosporine have been mainstays of systemic treatment for PG, although increasing evidence supports the use of biologic therapies, such as tumor necrosis factor-α inhibitors, for refractory cases of PG. Here, we review the clinical presentation and pathophysiology of PG, as well as its associated conditions, diagnostic work-up, and management.